The National Comprehensive Cancer Network (NCCN) risk-stratification system, categorizing intermediate-risk prostate cancer (PCa) into favorable and unfavorable subgroups, has unveiled better opportunities to personalize treatment in men with intermediate-risk PCa.¹ ASCO, the American Urological Association, and the American Society for Radiation Oncology guidelines do not provide any specific recommendation on the use of androgen deprivation therapy (ADT) in conjunction with radiotherapy in men with intermediate-risk PCa.^2,3 Nevertheless, there has been a substantial impetus toward avoiding ADT in favorable intermediate-risk (FIR) PCa to avert potential treatment-related morbidities of ADT.

中文翻译：

---

回复P. Ghadjar等。

国家综合癌症网络（NCCN）风险分层系统将中度风险前列腺癌（PCa）分为有利和不利的亚组，它为中度风险PCa男性提供了个性化治疗的更好机会。¹ ASCO，美国泌尿科协会和美国放射肿瘤学会指南未就中度风险PCa男性与雄激素剥夺疗法（ADT）联合放射疗法的使用提供任何具体建议。^[2,3]然而，在有利的中危（FIR）PCa中避免ADT产生了巨大的动力，从而避免了与治疗相关的ADT潜在发病率。